This issue opens with an editorial by Li et al., highlighting the inaugural EAACI Hong Kong Allergy School where global experts in drug allergy gathered under the theme “East Meets West” to call for harmonized international definitions of drug hypersensitivity and standardized criteria for identifying low-risk penicillin allergy, underscoring the urgent need to reduce mislabelling and advance safe, evidence-based delabelling practices worldwide. Leonardi et al. provide a comprehensive overview of the clinical presentations, diagnostic approaches, and treatment strategies for drug-induced ocular adverse events, integrating the latest literature and clinical guidelines. Cortellini et al. present data and recommendations on the characteristics of hypersensitivity reactions to antiplatelet drugs and the associated diagnostic procedures, to maximize their safety and effectiveness. Gelincik et al. review current knowledge on the pathomechanisms of hypersensitivity reactions to quinolones, including diagnostic tests and cross-reactivities, and propose a practical diagnostic approach for clinicians. Hutten et al. highlight significant discrepancies between studies on cross-allergy to beta-lactam antibiotics, particularly concerning recommendations for safe alternatives. Labella et al. investigate the utility of direct single-dose drug provocation testing without prior skin testing in adult European patients at low risk of penicillin allergy. Bilgic-Eltan et al. analyze the discrepancies between suspected and confirmed drug hypersensitivity in a well-defined cohort of patients with inborn errors of immunity.
Drug #hypersensitivity reactions (DHRs) constitute a major concern in clinical practice, as they compromise patient safety and restrict the use of essential medications.
#Allergy #Allergy_journal
journalallergy.com